The alarm keeps ringing. The cell gets confused about what's actually wrong.
In São Paulo, a team of biochemists followed an 11-year-old girl's suffering into the molecular interior of her own cells, and there found something the world had never seen before — a previously undocumented genetic variant quietly dismantling her nervous system. The disease, CONDSIAS, was itself only named in 2018, and this marks its first recorded appearance in South America. The discovery reminds us that rare does not mean unimportant: each singular case, when studied with care, can illuminate a diagnostic path for patients scattered across continents who have long gone unnamed.
- A child's worsening seizures, faltering coordination, and neurological decline — triggered by something as ordinary as an infection — pointed researchers toward a molecular alarm system stuck permanently on.
- The newly identified variant in the ADPRS gene had never been documented before, forcing scientists to prove it was truly the culprit rather than a genetic coincidence — a distinction that separates diagnosis from guesswork.
- Growing the girl's own skin cells in a laboratory dish, researchers found the protein ARH3 had nearly vanished, leaving her neurons unable to clear the chemical distress signals that should have faded once danger passed.
- The study's publication drew immediate international attention, with a European geneticist contacting the team about African patients carrying mutations in the same gene — suggesting the work's reach extends far beyond one child in Brazil.
- A trial of minocycline, the most accessible candidate therapy, yielded only modest results in the lab, underscoring that a correct diagnosis and an effective treatment remain two very different victories.
An 11-year-old girl in Brazil arrived at the University of São Paulo carrying a neurological puzzle: epilepsy that worsened with infections, difficulty coordinating her movements, developmental delays, and a progressive deterioration of her nervous system. Her condition matched CONDSIAS, a genetic disease so rare it had no name in most medical textbooks until 2018, one that causes the nervous system to degrade — especially when the body is under stress.
The girl carried two mutations in the ADPRS gene on chromosome 1. One was already known to cause the disease. The other had never been documented anywhere in the world. Biochemist Nicolas Carlos Hoch and his team at USP's Institute of Chemistry faced the central challenge of modern genetics: sequencing technology can find variants quickly and cheaply, but determining whether a variant actually explains a patient's illness is far harder.
To find out, the researchers grew the girl's skin cells in a laboratory and measured levels of ARH3, the protein the ADPRS gene produces. The protein had nearly disappeared. ARH3 normally acts as a molecular eraser — after cells mark DNA damage with a chemical signal called ADP-ribosylation, ARH3 clears that signal once the damage is repaired. Without it, the alarm accumulates, and neurons, which are especially sensitive to such imbalances, begin to fail.
Published in Neurology Genetics and supported by FAPESP, the study represents the first documented case of CONDSIAS in South America. Its impact spread quickly: after publication, a European geneticist working with African patients carrying mutations in the same gene contacted Hoch, hoping to interpret whether those variants might also cause the disease. For Hoch, this cross-continental reach was the work's deepest value.
The team also tested minocycline, an inexpensive antibiotic the girl had already been taking experimentally, to see whether blocking the chemical signal at its source might help. The results were sobering — minocycline showed only a small effect compared to purpose-built PARP inhibitors. The study thus points in two directions at once: toward faster, more certain diagnoses for patients around the world, and toward the longer, harder work of finding treatments that truly address the disease.
An 11-year-old girl in Brazil arrived at the University of São Paulo with a puzzle that would take researchers into the molecular machinery of her own cells. She had epilepsy that worsened with infections, trouble coordinating her movements, developmental delays, and a progressive deterioration of her nervous system. Her symptoms matched a disease so rare that when it was first described in 2018, it had no name in most medical textbooks: CONDSIAS, a genetic condition that emerges in early childhood and causes the nervous system to degrade, especially when the body is under stress.
The girl carried two mutations in a gene called ADPRS, located on chromosome 1. One of them was already known to cause the disease. The other was entirely new—never documented before. Nicolas Carlos Hoch, a biochemist at the University of São Paulo's Institute of Chemistry, and his team faced the central problem of modern genetics: finding a variant in someone's DNA is no longer the hard part. Sequencing technology has made that fast and cheap. The hard part is knowing whether that variant actually explains why the person is sick. "When you analyze a patient's DNA, it's common to find more than one rare variant," Hoch explained. "The question is whether that variant explains the patient's symptoms or not."
To answer that question, the researchers took a sample of skin from the girl and grew her cells in a laboratory dish. Inside those cells, they looked for a protein called ARH3, which is produced by the ADPRS gene. What they found was striking: the protein was barely there. The combination of her two mutations had essentially erased it. ARH3 functions as a molecular eraser. When cells detect damage—a break in DNA, for instance—they mark the problem with a chemical modification called ADP-ribosilation, a kind of molecular alarm. Once the damage is fixed, that alarm needs to be switched off. Without ARH3 to remove the signal, it accumulates. In neurons, which are exquisitely sensitive to molecular imbalances, this buildup can cripple the cell's ability to function. The girl's cells could not clear these signals properly, and her nervous system paid the price.
The discovery, published in the journal Neurology Genetics and supported by the São Paulo Research Foundation, represents the first documented case of CONDSIAS in South America. It also opens a door for diagnosis elsewhere. After the paper appeared, a European geneticist working with African patients who carried mutations in the same ADPRS gene reached out to Hoch, wanting to know whether the variants he was seeing might also cause the disease. For Hoch, this was the real impact of the work: giving doctors around the world a molecular foothold to interpret rare genetic changes and make faster, more certain diagnoses.
But the study also ventured into treatment. Because no specific therapy exists for CONDSIAS, the researchers tested whether they could prevent the disease's core problem from developing in the first place. If the trouble is that cells cannot remove the ADP-ribosilation signal, perhaps they could stop the signal from being made at all. They chose to test minocycline, an antibiotic from the tetracycline family. It was cheap, widely available, and older research suggested it might block PARP, the enzyme that initiates the problematic signal. Some PARP inhibitors developed for cancer exist, but they are expensive and not routinely used in rare genetic diseases. Minocycline seemed like a more accessible option—and notably, the girl herself had already been taking it experimentally.
When the team tested minocycline in the lab, though, the results were disappointing. It had only a small effect compared to PARP inhibitors designed specifically for this purpose. The finding counseled caution. It suggested that while the girl and others like her might benefit from more targeted therapies, minocycline alone was not the answer. The work, then, points in two directions at once: toward better diagnosis for patients around the world carrying rare variants in ADPRS, and toward the harder, longer work of finding treatments that actually work.
Notable Quotes
When you analyze a patient's DNA, it's common to find more than one rare variant. The question is whether that variant explains the patient's symptoms or not.— Nicolas Carlos Hoch, biochemist at USP
It's good to see that these things have impact on clinical management. People read it and it reaches someone.— Nicolas Carlos Hoch
The Hearth Conversation Another angle on the story
Why does it matter that this is the first case documented in South America?
It's not just geography. It means the disease exists in places where genetic sequencing is less common, where patients might go undiagnosed for years. Once you document a case and publish it, other doctors in the region can recognize it. They stop thinking the child has something else.
The girl had one known mutation and one new one. Why did having two matter so much?
Because one mutation alone might not have been enough to destroy the protein. But together, they erased it almost completely. That's what made it possible to see the mechanism—to understand what was actually breaking down in her cells.
You tested minocycline because the girl was already taking it. What does that tell you?
That sometimes patients and families discover things before science does. They try something, they notice it might help, and then researchers have to figure out whether there's actually a reason it works. In this case, there wasn't—not enough to matter. But you have to check.
If there's no good treatment yet, what's the practical value of knowing the genetic cause?
Diagnosis is not nothing. It ends the search. Parents stop wondering what's wrong. Doctors can predict what might happen next. And it opens the door to finding real treatments. You can't fix something if you don't know what's broken.
The protein ARH3 is described as an eraser. What happens if you never erase the signal?
The alarm keeps ringing. The cell gets confused about what's actually wrong. In neurons especially, that confusion is catastrophic. They're already running on a knife's edge, managing thousands of signals at once. Add noise to that system and it collapses.
What comes next for this girl and others like her?
Better diagnosis, certainly. But the real work is finding drugs that actually stop the disease. The study shows minocycline isn't it. So researchers will keep looking—at other PARP inhibitors, at ways to stabilize the protein, at things we haven't thought of yet.